Octreotide acetate: Additional Phase III data

Chiasma reported additional data from an open-label, international Phase III trial in 151 evaluable adults with acromegaly showing that baseline control on injectable somatostatin analogs could predict a subsequent response to oral octreotide, defined as maintaining IGF-1 levels of <1.3 times the upper limit of normal (ULN) and integrated growth hormone levels of <2.5 ng/mL measured over 2 hours. Specifically, response rates to oral octreotide were 76% for patients completely controlled on injections, defined as IGF-1 levels of <=1 time the ULN and integrated growth hormone levels of <2.5 ng/mL; 44% for patients partially controlled on injections, defined as IGF-1 levels of 1-1.3 times the ULN and integrated growth hormone levels of <2.5 ng/mL; and 24% for patients uncontrolled on injections. ...